Halozyme Therapeutics cut to market perform from outperform; price target raised to $117
HALO•Leerink Partners cut its rating on Halozyme Therapeutics to market perform from outperform and raised its price target to $117 from $110.
Related News
Bombardier: UBS raises target price to C$356 from C$335
BDRBF•
Nasdaq rebounds as chip stocks recover from steep losses
QQQ•
Analysts revise targets for Airbnb, Cloudflare and Royal Gold
ABNB•
Gildan Activewear Inc.: UBS cuts to neutral from buy, cuts target price to $38 from $71
GIL•
Oklo, U.S. Forged Rings partner on manufacturing for future Aurora deployments
OKLO•